The Group’s proprietary chlorine dioxide formulation and the Company addresses three distinct markets:
- The Human Healthcare market (hospital infection prevention - via the Tristel brand) represents 85% of Group sales
- The Contamination Control market (control of contamination in critical environments - via the Crystel brand)
- The Animal Healthcare market (veterinary practice infection prevention - via the Anistel brand)
Tristel’s proprietary chlorine dioxide chemistry has two defining features: first, it kills bacterial spores very quickly; second, it is safe to use. As a consequence, Tristel’s surface disinfectants provide the most effective stratagem to control Clostridium difficile, one of the most problematic pathogens in hospitals.
For the year ending 30th June 2015 turnover was up 14% to £15.3m, pre-tax profit up 44% to £2.6m and basic earnings per share up a whopping 67% to 5.44p. The full year dividend per share was increased to 5.72p (2014: 1.62p) and included a special…
Register to continue reading this article.
Already a member? Login
For access to the top news and insights from the investment worldREGISTER FREE TODAY
It’s not always easy to keep track of your investments. Sometimes big news gets hidden in…
The value of Tristel’s medical device decontamination products are highlighted by the fact that the company…